Stay updated with breaking news from Phasei First Time. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Mission Therapeutics ("Mission" or the "Company"), a clinical-stage biotech developing first-in-class therapeutics targeting mitophagy, today...
14 Dec 2023 - Mission gains clearance from US FDA for Phase II trial of MTX652 after it receives official approval of its Investigational New Drug application ...
The rising incidence of COPD and the exacerbations associated with it have been instrumental in piquing the interest of pharma players and academia in...
First non-antibiotic macrolide to go into clinical development targeting COPD Safety, tolerability and pharmacokinetic endpoints met Phase II planning underway EpiEndo Pharmaceuticals
First non-antibiotic macrolide to go into clinical development – targeting COPDSafety, tolerability and pharmacokinetic endpoints metPhase II planning underwayREYKJAVIK, Iceland, May 18, 2022 / B3C newswire / -- EpiEndo Pharmaceuticals (‘EpiEndo’), the clinical-stage biopharmaceutical company developing disease-modi...